Media coverage about Affymetrix (NASDAQ:AFFX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Affymetrix earned a news impact score of 0.09 on Accern’s scale. Accern also gave news headlines about the scientific and technical instruments company an impact score of 46.0610351983385 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Affymetrix (NASDAQ AFFX) traded up $0.02 during midday trading on Wednesday, hitting $14.01. 5,030,400 shares of the company traded hands, compared to its average volume of 3,494,434. Affymetrix has a 12 month low of $8.28 and a 12 month high of $16.15.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Affymetrix (AFFX) Stock Price” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://stocknewstimes.com/2017/11/15/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-affymetrix-affx-stock-price.html.
Affymetrix Company Profile
Affymetrix, Inc (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry.
Receive News & Ratings for Affymetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.